The indole scaffold has been recognized, over the years, as a model for the synthesis of compounds with anticancer activity by dint of its substantiated ability to act via multiple mechanisms, which also involves the inhibition of enzymes engaged in DNA replication. In this regard, a new series of indole and pyranoindole derivatives have been prepared, some of which showed good antitumor activity and proved their inhibitory effects on the tubulin target. The anticancer activity of the newly synthesized compounds has been evaluated on breast cancer cell lines, as MCF-7 and MDA-MB231, cervical cancer cells line HeLa and Ishikawa endometrial cancer cell line. Among the compounds under study, 7 exhibited a good antitumor activity on HeLa cell line (IC₅₀ = 3.6 ± 0.5), leading to cell death by apoptosis due to the inhibition of tubulin polymerization, which demonstrated that the compound can explicate its function in a similar way to Vinblastine, a well-known inhibitor of tubulin polymerization. The data were also confirmed by in silico assays. No cytotoxicity against normal cells has been detected. Furthermore, in order to investigate the antioxidant properties, DPPH and ABTS tests were performed, together with fluorescence assays on 3T3-L1 cells. All our findings taken together led us to consider compound 7 a favourable candidate for the battle against cancer.

多年来，吲哚支架已经被认为是合成具有抗癌活性的化合物的模型，这是由于其具有通过多种机制起作用的可靠能力，这也涉及抑制参与DNA复制的酶。在这方面，已经制备了一系列新的吲哚和吡喃并吲哚衍生物，其中一些表现出良好的抗肿瘤活性并证明了它们对微管蛋白靶的抑制作用。已经评估了新合成化合物对乳腺癌细胞系MCF-7和MDA-MB231，宫颈癌细胞系HeLa和石川子宫内膜癌细胞系的抗癌活性。在研究的化合物中，有7种对HeLa细胞系具有良好的抗肿瘤活性（IC ₅₀ ＝ 3.6±0.5），由于微管蛋白聚合的抑制导致细胞凋亡导致细胞死亡，这表明该化合物可以以与众所周知的微管蛋白聚合抑制剂长春花碱相似的方式发挥其功能。数据也通过计算机分析证实。没有检测到针对正常细胞的细胞毒性。此外，为了研究抗氧化性能，对3T3-L1细胞进行了DPPH和ABTS测试以及荧光测定。我们所有的发现加在一起，使我们认为化合物7是对抗癌症的有利候选药物。